Method of engineering multi-input signal sensitive t cell for immunotherapy
US-2017073423-A1 · Mar 16, 2017 · US
Generating mammalian T cell activation inducible synthetic promoters (SYN+PRO) to improve T cell therapy
US11851649B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11851649-B2 |
| Application number | US-201816613025-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 15, 2018 |
| Priority date | May 17, 2017 |
| Publication date | Dec 26, 2023 |
| Grant date | Dec 26, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Aspects of the invention described herein relate to methods of making and using inducible promoters for transgene expression. The inducible promoters are derived from the NFAT-RE inducible system and are used to improve or enhance T cell survival and proliferation.
First claim
Opening claim text (preview).
What is claimed is: 1. An isolated nucleic acid comprising a promoter comprising a transcription response element having a sequence with at least 98% sequence identity to the sequence as set forth in SEQ ID NO: 7. 2. The isolated nucleic acid of claim 1 , wherein the transcription response element comprises a sequence having at least 99% sequence identity to the sequence as set forth in SEQ ID NO: 7. 3. The isolated nucleic acid of claim 1 , wherein the transcription response element comprises the sequence as set forth in SEQ ID NO: 7. 4. The isolated nucleic acid of claim 1 , wherein the promoter further comprises an IL2 minimal promoter. 5. The isolated nucleic acid of claim 1 , wherein the isolated nucleic acid is operably linked to a sequence encoding a payload. 6. The isolated nucleic acid of claim 5 , wherein the payload comprises CD122, CD127, CD360, caSTAT5, dnSHP1, or dnSHP2; PD1:MyD88, PD1:CD28, CD200:CD28, or miRNA155. 7. A vector comprising a nucleic acid comprising a promoter comprising a transcription response element having a sequence with at least 98% sequence identity to the sequence as set forth in SEQ ID NO: 7, wherein the nucleic acid is operably linked to a sequence encoding a payload. 8. The vector of claim 7 , wherein the transcription response element comprises a sequence having at least 99% sequence identity to the sequence as set forth in SEQ ID NO: 7. 9. The vector of claim 7 , wherein the transcription response element comprises the sequence as set forth in SEQ ID NO: 7. 10. The vector of claim 7 , wherein the promoter further comprises a minimal IL2 promoter. 11. The vector of claim 7 , wherein the vector comprises a viral vector, a transposase based minicircle, or a nanoplasmid. 12. The vector of claim 7 , wherein the vector comprises a lentiviral vector. 13. The vector of claim 7 , wherein the payload comprises CD122, CD127, CD360, caSTAT5, dnSHP1, or dnSHP2; PD1:MyD88, PD1:CD28, CD200:CD28, or miRNA155. 14. A cell comprising: the vector of claim 7 . 15. The cell of claim 14 , wherein the transcription response element comprises a sequence having at least 99% sequence identity to the sequence as set forth in SEQ ID NO: 7. 16. The cell of claim 14 , wherein the transcription response element comprises the sequence as set forth in SEQ ID NO: 7. 17. The cell of claim 14 , wherein the promoter further comprises a minimal IL2 promoter. 18. The cell of claim 14 , wherein the cell is a T cell or a hematopoietic stem cell. 19. The cell of claim 18 , wherein the T cell is a CD4+ T cell or a CD8+ T cell. 20. The cell of claim 14 , wherein the cell further comprises a nucleic acid encoding a chimeric antigen receptor (CAR).
Assignees
Inventors
Classifications
CD19 or B4 · CPC title
Chimeric antigen receptors [CAR] · CPC title
T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title
characterised by the dose, timing or administration schedule · CPC title
Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11851649B2 cover?
- Aspects of the invention described herein relate to methods of making and using inducible promoters for transgene expression. The inducible promoters are derived from the NFAT-RE inducible system and are used to improve or enhance T cell survival and proliferation.
- Who is the assignee on this patent?
- Seattle Childrens Hospital
- What technology area does this patent fall under?
- Primary CPC classification C12N15/113. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).